INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on November 12, 2020. The report details the entry into a material definitive agreement regarding a public offering of common stock and the company's listing on the NASDAQ Capital Market.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. The primary financial data relates to the proposed capital raise:
- Offering Size: 3,625,000 shares of Common Stock (Firm Shares).
- Public Offering Price: $3.20 per share.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 543,750 additional shares.
- Expected Net Proceeds: Approximately $10.1 million (after underwriting discounts, commissions, and estimated offering expenses).
- Expected Closing Date: November 17, 2020.
Material Changes
The material change reported is the execution of an underwriting agreement with Roth Capital Partners, LLC, as representative of the underwriters. This agreement facilitates the follow-on public offering and the subsequent listing of the company's common stock on the NASDAQ Capital Market.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance on revenue or earnings. Management commentary is limited to the announcement of the pricing and listing. The document notes that the Underwriting Agreement contains customary representations, warranties, covenants, and indemnification obligations. The closing of the offering is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected November 17, 2020) and whether the over-allotment option was exercised.
- Confirm the actual net proceeds received after all expenses are finalized.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Check subsequent filings for the official confirmation of the NASDAQ Capital Market listing.